Introduction
Mutations in the Wilms tumor 1 gene (WT1) occur in approximately 10% of adults with cytogenetically normal acute myeloid leukemia (CN-AML), and have been reported to confer a worse outcome [1] [2] [3] [4] [5] [6] or to have no prognostic impact. [7] [8] The synonymous single nucleotide polymorphism (SNP) rs16754 (dbSNP Build ID: 131), 9 located in exon 7 of the WT1 gene, which is a hot spot for WT1 mutations in AML, has also recently been reported to be associated with outcome. 8, [10] [11] [12] [13] SNP rs16754 has two alleles which differ by harboring the nucleotides adenine (A) or guanine (G). They are present in a homozygous (denoted WT1 AA or WT1 GG , respectively) or heterozygous state (WT1 AG ).
Damm et al. 8 reported that among younger adults (17-60 years) with CN-AML, those who were homozygous for the A allele (WT1 AA ) had a trend for lower complete remission (CR) rates, and a significantly shorter relapse-free survival (RFS) and overall survival (OS) than patients harboring at least one G allele (WT1 AG /WT1 GG ). This adverse prognostic impact of the WT1 AA genotype on RFS and OS remained significant in multivariable analyses considering other prognostic markers, and was most pronounced in the high-risk subset of patients with FLT3-internal tandem duplication (FLT3-ITD) and/or NPM1 wild-type. 8 In contrast, Renneville et al. 10 described in a preliminary report that among older CN-AML patients (aged 50 to 70 years) those with WT1 AA had better outcomes than the WT1 AG /WT1 GG patient group. In pediatric AML, SNP rs16754 was not found to be of prognostic significance in two independent cohorts of CN-AML Thus, to further clarify the clinical significance of the rs16754 polymorphism, we investigated the prognostic impact of its genotypes in a relatively large group of 433 intensively treated de novo CN-AML patients aged 18 to 83 years who were comprehensively characterized for other molecular markers. Moreover, to gain insights into the potential biologic diversity related to the rs16754 polymorphism, we compared the gene-and, for the first time, the microRNA-expression profiles according to the rs16754 genotypes.
Design and Methods

Patients, Treatment and Cytogenetic Analysis
We studied pretreatment bone marrow (BM) or blood with ≥20% blasts from 433 patients enrolled on cytarabine and daunorubicin-based Cancer and Leukemia Group B (CALGB) first-line treatment protocols as summarized in the Supplementary Data.
Patients with preceding hematologic disorders or treatment-related AML were excluded.
Per treatment protocols, no patient received allogeneic stem-cell transplantation (SCT) in first CR. The median follow-up for patients alive was 6.5 years (range: 2.3-11.7 years).
Cytogenetic analyses at diagnosis were performed by CALGB-approved institutional cytogenetic laboratories, and the results confirmed by central karyotype review. 14 The diagnosis of normal cytogenetics was made based on the analysis of ≥20 metaphases in BM specimens cultured for 24-48 hours.
All patients provided written informed consent, and all study protocols were in accordance with the Declaration of Helsinki and approved by Institutional Review Boards at each center.
Analysis of SNP rs16754 and Other Molecular Markers
Tissue preparation is detailed in the Supplementary Data. Genomic DNA and total RNA extraction and quality control of the extracted nucleic acids were performed as reported elsewhere. 15 WT1 exon 7 was amplified from genomic DNA in a polymerase chain reaction, and SNP rs16754 was assessed by direct sequencing. WT1 exon 7 and 9 mutations, 2, 16, 17 
Genome-wide Expression Analyses
Gene-expression profiling was performed using Affymetrix U133 plus 2.0 arrays All analyses were performed by the CALGB Statistical Center. 
Results
Frequencies and Pretreatment Features of the rs16754 Genotypes
Outcome According to the rs16754 Genotypes
In the entire study population, we observed no significant outcome differences among WT1 AA , WT1 AG and WT1 GG patients ( Pair-wise comparisons between the patients according to their rs16754 genotypes revealed no significant gene-or microRNA-expression signature associated with the rs16754 genotypes in the younger or older patients. Moreover, in unsupervised cluster analyses of the gene-and microRNA-expression profiles, there were no evident patterns of clustering of the patients according to the rs16754 genotypes ( Figure 2 ).
Discussion
The conflicting reports concerning the prognostic significance of SNP rs16754 8, [10] [11] [12] [13] prompted us to evaluate the clinical impact of this polymorphism in a relatively large cohort of intensively treated de novo CN-AML patients whom we have previously comprehensively characterized at the molecular level. 15 To gain insights into the biologic features of the polymorphism, we also examined the gene-and microRNA-expression profiles according to the rs16754 genotypes.
The frequencies and the race distribution of the rs16754 genotypes in our CN-AML cohort were in accordance with those expected in a normal population (dbSNP Build ID:
131). 9 This suggests that none of the rs16754 genotypes is associated with a predisposition to AML. In addition to being more frequent in non-Caucasians, our results also suggest that the WT1 GG genotype might be associated with other distinct pretreatment characteristics, such as a higher frequency of leukemic skin infiltrates and TET2 mutations. Based on the current data, the role of SNP rs16754 in predicting outcome of CN-AML patients appears to be minor when compared with the aforementioned gene mutations.
Although in some studies specific SNP rs16754 genotypes have been shown to be associated with outcome, the results are inconsistent. 8, [10] [11] [12] [13] Thus, further molecular studies should clarify the prognostic role of the rs16754 genotypes before testing for SNP rs16754 should be considered for inclusion in the work-up of patients with CN-AML.
SNP rs16754 attracted particular attention because of its localization in a "hot spot" for (56) 177 (57) 57 (51) 8 (67) .27 .57 .37 Male sex, no. (%) 216 (50) 152 (49) 58 (52) 6 (50 (25) 90 (30) 75 (25) 45 (15) 6 (2) 4 (2) 50 (24) 64 (30) 53 (25) 36 (17) 3 (1) 4 (5) 21 (27) 24 (30) 19 (24) 8 (10) 3 (4) 1 (11) 2 (22) 2 (22) 3 (33) 1 ( (5) 23 (5) 34 (8) 28 (7) 41 (10) 2 (<1) 81 (27) 1 (<1) 15 (5) 17 (6) 22 (7) 18 (6) 34 (11) 1 (<1) 25 (23) 1 (1) 6 (5) 5 (5) 10 (9) 7 (6) 5 (5) 1 (1) 5 (42) 0 (0) 0 (0) 1 (8) (39) 187 (61) 122 (39) 70 (63) 42 (38) 6 (50) 6 (50) .74 .55 .53
FLT3-ITD, no. (%) Positive Negative
149 (34) 284 (66) 108 (35) 201 (65) 36 (32) 76 (68) 5 (42) 7 (58) . (66) 105 (34) 204 (66) 41 (37) 71 (63) 2 (17) 10 (83) . 64 .35 .21
FLT3-TKD, no. (%) Positive Negative
42 (10) 388 (90) 31 (10) 276 (90) 10 (9) 101 (91) 1 (8) 11 (92) .85
1.0 (91) 23 (7) 286 (93) 15 (13) 97 (87) 1 (8) 11 (92) .08
1.0 (85) 48 (16) 259 (84) 14 (13) 98 (88) 3 (25) 9 (75) .
53
.42 .21
MLL-PTD, no. (%)
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Definition of Clinical End Points
CR required an absolute neutrophil count ≥1,500/µL, platelet count ≥100,000/µL, no leukemic blasts in the blood, BM cellularity greater than 20% with maturation of all cell lines, no Auer rods, less than 5% BM blast cells, and no evidence of extramedullary leukemia, all of which had persisted for at least 1 month. 10 Relapse was defined by ≥5%
BM blasts, circulating leukemic blasts, or the development of extramedullary leukemia.
Disease-free survival (DFS) was measured from the date of CR until the date of relapse or death; patients alive and relapse-free at last follow-up were censored. Overall survival (OS) was measured from the date on study until the date of death, and patients alive at last follow-up were censored. (11) 66 (93) 5 (7) 7 (70) (17) 165 (83) 17 (24) 54 (76) 1 (10) 9 (90) . (47) 24 (49) 25 (51) 3 (33) 6 (67) . * FAB are centrally reviewed. ** For patients on CALGB 9621, cut point was the same as in Marcucci et al. (J Clin Oncol. 2005; 23(36):9234-42) . For patients on all other protocols, median ERG expression value was used for cut point. *** Median expression was used as cut point. Patients are sorted by duration of disease-free survival.
Supplementary
Pt: patient; FLT3-ITD: internal tandem duplication of the FLT3 gene; FLT3-TKD: tyrosine kinase domain mutations of the FLT3 gene; MLL-PTD: partial tandem duplication of the MLL gene; n/a: not applicable since patient did not achieve a complete remission.
* Patient had two mutations in CEBPA. ** Patient had a mutation in IDH2 codon R140. *** For patients on CALGB 9621, cut point was the same as in Marcucci et al. (J Clin Oncol. 2005; 23(36):9234-42) . For patients on all other protocols, median ERG expression value was used for cut point. **** Median expression was used as cut point.
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